PDCD1 and hepatocellular carcinoma: The CheckMate 040 trial showed patients with advanced HCC had an objective response to nivolumab (monoclonal antibody targeting PD-1) monotherapy; however, the phase III CheckMate-459 trial, which compared nivolumab to sorafenib, did not reach statistical significance for median OS (16.4 vs. 14.7 months, HR 0.85; 95% CI, 0.72–1.02) [82,83].